Julio C. Chávez

2006–2025 年に発表

別表記
Julio C Chávez
128
論文数
19,076
被引用数
54
h 指数
118
i10 指数

被引用数

Julio C. Chávez の年別被引用数1990 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 1 件2001 年: 被引用 3 件2005 年: 被引用 1 件2006 年: 被引用 4 件2008 年: 被引用 3 件2009 年: 被引用 1 件2012 年: 被引用 4 件2013 年: 被引用 2 件2014 年: 被引用 7 件2015 年: 被引用 12 件2016 年: 被引用 11 件2017 年: 被引用 40 件2018 年: 被引用 140 件2019 年: 被引用 625 件2020 年: 被引用 1,062 件2021 年: 被引用 1,360 件2022 年: 被引用 1,291 件2023 年: 被引用 1,056 件2024 年: 被引用 1,732 件2025 年: 被引用 816 件2026 年: 被引用 11 件1993〜2000 年は被引用が無いため表示していません2002〜2004 年は被引用が無いため表示していません2007 年は被引用が無いため表示していません2010〜2011 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,623 件、この内訳の 31.2%中国: 引用元論文 912 件、この内訳の 10.8%ドイツ: 引用元論文 566 件、この内訳の 6.7%イギリス: 引用元論文 449 件、この内訳の 5.3%イタリア: 引用元論文 417 件、この内訳の 5%フランス: 引用元論文 372 件、この内訳の 4.4%スペイン: 引用元論文 349 件、この内訳の 4.2%カナダ: 引用元論文 266 件、この内訳の 3.2%オーストラリア: 引用元論文 215 件、この内訳の 2.6%スイス: 引用元論文 211 件、この内訳の 2.5%オランダ: 引用元論文 178 件、この内訳の 2.1%日本: 引用元論文 137 件、この内訳の 1.6%
0%31.2%その他 20.4%

分野

  • Medicine89.7%
  • Biochemistry, Genetics and Molecular Biology5.2%
  • Immunology and Microbiology3.3%
  • Engineering0.5%
  • Computer Science0.2%
  • Materials Science0.2%
  • その他0.9%

トピック

  • CAR-T cell therapy research25.2%
  • Lymphoma Diagnosis and Treatment8.6%
  • Virus-based gene therapy research6.1%
  • Immune Cell Function and Interaction4.9%
  • Nanowire Synthesis and Applications4.3%
  • Viral Infectious Diseases and Gene Expression in Insects3.6%
  • その他47.3%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 被引用: 5,915

  2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sattva S. Neelapu - The Lancet Oncology 2018 被引用: 2,251

  3. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 617

  4. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 被引用: 527

  5. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 786

  6. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 228

  7. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2022 被引用: 237

  8. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

    著者: , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 283

  9. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2020 被引用: 271

  10. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 292

  11. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2019 被引用: 344

  12. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    著者: , , , , , , , , , , , , , , , - Molecular Therapy 2017 被引用: 619

  13. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , - Blood Advances 2020 被引用: 242

  14. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 141

  15. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 被引用: 88

  16. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thiéblemont, Stephen J. Schuster - Blood 2024 被引用: 93

  17. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

    著者: , , - Therapeutic Advances in Hematology 2019 被引用: 223

  18. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2019 被引用: 162

  19. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nishitha Reddy, Shaoying Li, Caitlin E. Handler, Christopher R. Flowers, Jonathon B. Cohen, Kristie A. Blum, Kevin Song, Haowei Sun, Oliver W. Press, Ryan D. Cassaday, Jesse Jaso, L. Jeffrey Medeiros, Aliyah R. Sohani, Jeremy S. Abramson - Blood 2014 被引用: 466

  20. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie José Kersten - Blood 2022 被引用: 75

  21. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Lunning, Saurabh Dahiya - Journal of Clinical Oncology 2024 被引用: 73

  22. Cytokine Release Syndrome: Current Perspectives

    著者: , , , - ImmunoTargets and Therapy 2019 被引用: 176

  23. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 161

  24. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Y. Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey M. Switchenko, Jonathon B. Cohen, Craig A. Portell - Blood 2021 被引用: 94